膝骨关节炎药物市场机会、成长动力、产业趋势分析及 2025 - 2034 年预测

2024 年全球膝关节骨性关节炎药物市场规模达 67 亿美元，预计 2025 年至 2034 年的复合年增长率为 8%。这一增长主要是由于人口老化、久坐不动的生活方式和肥胖率上升导致膝关节骨性关节炎盛行率上升，这些因素增加了对有效治疗的需求。市场也受益于人们对早期诊断和治疗的认识不断提高，这鼓励了及时的医疗干预。此外，药物配方的进步，包括联合疗法和缓释选项，正在改善治疗效果并促进市场成长。透明质酸 (HA) 黏弹性材料在骨科和运动医学中的使用率更高，进一步促进了市场积极的发展轨迹。

膝关节骨关节炎药物主要用于控制患者的疼痛、发炎和病情进展。这些药物选择包括非类固醇抗发炎药、皮质类固醇、黏液补充剂、镇痛药和其他旨在缓解症状和延缓手术干预所需的药物类型。其中，非类固醇抗发炎药的收入最高，2024 年将达到 24 亿美元，预计到 2034 年将成长到 50 亿美元，复合年增长率为 7.7%。非类固醇抗发炎药物因其广泛用于治疗疼痛和发炎的一线治疗而继续占据市场主导地位。布洛芬、萘普生和塞来昔布等药物由于其功效、可用性和成本效益仍然是受欢迎的选择。局部用药和 COX-2 选择性抑制剂等更安全、更有效的製剂的进步进一步促进了该领域的成长。

依给药途径划分，2024 年，肠外给药占最大份额，为 51.3%，这是因为与口服和外用药物相比，肠外给药具有起效快、生物利用度更高、缓解疼痛时间更长等特征。肠外给药包括注射皮质类固醇、黏弹性补充剂（HA注射）和各种生物製剂，通常用于口服治疗不足的中度至重度OA病例。人们对微创技术和长效注射剂的日益青睐也推动了该领域的成长。再生疗法的进一步发展，包括缓释製剂、富血小板血浆 (PRP) 和干细胞疗法，预计将促进该领域的成长。

市场按年龄细分为 18-44 岁、45-64 岁和 65 岁以上，其中 65 岁以上年龄层预计将保持突出地位，增长率为 7.6%，到 ​​2034 年将达到 60 亿美元。老化会降低关节灵活性、增加发炎并导致软骨退化，从而导致 OA 盛行率上升。因此，预期寿命的增加、对治疗方案认识的提高以及医疗保健支出的增加正在推动这一人群对膝关节骨关节炎药物的需求。此外，对长效和微创解决方案的偏好继续增强整个市场的需求。

2024年，美国继续保持北美膝关节骨关节炎药物市场的领先地位，估值从2023年的24亿美元成长至26亿美元。膝关节骨关节炎的高盛行率、人口老化以及对微创治疗的日益偏好刺激了对先进疗法的需求，为市场扩张做出了重要贡献。

目录

第一章：方法论与范围

第二章：执行摘要

第三章：行业洞察

• 产业生态系统分析
• 产业衝击力
  • 成长动力
    • 膝骨关节炎盛行率上升
    • 非手术治疗的偏好日益增长
    • 药物配方的进步
    • 提高认识和早期诊断
  • 产业陷阱与挑战
    • 治疗费用高
    • 严格的监管审批
• 成长潜力分析
• 监管格局
• 管道分析
• 未来市场趋势
• 波特的分析
• PESTEL分析

第四章：竞争格局

• 介绍
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 策略仪表板

第五章：市场估计与预测：按药物类型，2021 - 2034 年

• 主要趋势
• 非类固醇抗发炎药（NSAID）
• 皮质类固醇
• 黏液补充疗法
  • 单次注射
  • 3次注射
  • 5次注射
• 止痛药
• 其他药物类型

第六章：市场估计与预测：按管理路线，2021 - 2034 年

• 主要趋势
• 口服
• 肠外
• 外用

第七章：市场估计与预测：按年龄组，2021 - 2034 年

• 主要趋势
• 18 - 44
• 45 - 64
• 65岁以上

第八章：市场估计与预测：按地区，2021 - 2034 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第九章：公司简介

• Anika Therapeutics
• Avanos
• Biotech Healthcare
• Bioventus
• Ferring Pharmaceuticals
• Fidia Pharma
• GlaxoSmithKline (GSK)
• Haleon
• Kenvue
• Organon LLC
• Pacira Pharmaceuticals
• Pfizer
• Premier Surgical
• Sanofi
• Stellar Pharmaceuticals

The Global Knee Osteoarthritis Drugs Market reached USD 6.7 billion in 2024 and is expected to grow at a CAGR of 8% from 2025 to 2034. This growth is primarily driven by the rising prevalence of knee OA due to an aging population, sedentary lifestyles, and increasing obesity rates, which have amplified the need for effective treatments. The market is also benefiting from growing awareness about early diagnosis and treatment, which encourages timely medical intervention. Additionally, advancements in drug formulations, including combination therapies and extended-release options, are enhancing treatment outcomes and boosting market growth. Higher usage of hyaluronic acid (HA) viscoelastic in orthopedics and sports medicine is further contributing to the market's positive trajectory.

Knee OA drugs primarily manage pain, inflammation, and disease progression in affected patients. These pharmaceutical options include NSAIDs, corticosteroids, viscosupplementation, analgesics, and other drug types aimed at alleviating symptoms and delaying the need for surgical interventions. Among these, NSAIDs generated the highest revenue, reaching USD 2.4 billion in 2024 and projected to grow to USD 5 billion by 2034, with a CAGR of 7.7%. NSAIDs continue to dominate the market due to their widespread use as a first-line treatment for pain and inflammation. Medications such as ibuprofen, naproxen, and celecoxib remain popular choices due to their efficacy, availability, and cost-effectiveness. The segment growth is further reinforced by advancements in safer and more effective formulations, such as topical options and COX-2 selective inhibitors.

By route of administration, the parenteral segment held the largest share of 51.3% in 2024, owing to its rapid onset of action, higher bioavailability, and extended duration of pain relief compared to oral and topical options. Parenteral administration includes injectable corticosteroids, viscosupplementation (HA injections), and various biologics, which are commonly used for moderate to severe OA cases where oral treatments prove inadequate. The segment growth is also driven by an increasing preference for minimally invasive techniques and long-acting injectables. Further advancements in regenerative therapies, including sustained-release formulations, platelet-rich plasma (PRP), and stem cell therapies, are expected to boost segment growth.

The market is segmented by age group into 18-44, 45-64, and above 65, with the above 65 segment projected to maintain a prominent position, growing at a rate of 7.6% and reaching USD 6 billion by 2034. Aging reduces joint flexibility, increases inflammation, and leads to cartilage degeneration, which contributes to the rising prevalence of OA. As a result, increased life expectancy, rising awareness about treatment options, and higher healthcare spending are fueling the demand for knee OA drugs within this demographic. Additionally, the preference for long-acting and minimally invasive solutions continues to strengthen demand across the market.

In 2024, the U.S. maintained a leading position in the North American knee OA drugs market, with a valuation of USD 2.6 billion, up from USD 2.4 billion in 2023. The high prevalence of knee OA, an aging population, and a growing preference for minimally invasive treatments have fueled the demand for advanced therapies, contributing significantly to market expansion.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of knee OA
    • 3.2.1.2 Growing preference for non-surgical treatments
    • 3.2.1.3 Advancements in drug formulations
    • 3.2.1.4 Rising awareness and early diagnosis
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High treatment cost
    • 3.2.2.2 Stringent regulatory approvals
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Future market trends
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Non-steroidal anti-inflammatory drugs (NSAIDs)
• 5.3 Corticosteroids
• 5.4 Viscosupplementation
  • 5.4.1 Single injection
  • 5.4.2 3 injections
  • 5.4.3 5 injections
• 5.5 Analgesics
• 5.6 Other drug types

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Oral
• 6.3 Parenteral
• 6.4 Topical

Chapter 7 Market Estimates and Forecast, By Age Group, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 18 - 44
• 7.3 45 - 64
• 7.4 Above 65

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 India
  • 8.4.3 Japan
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 Anika Therapeutics
• 9.2 Avanos
• 9.3 Biotech Healthcare
• 9.4 Bioventus
• 9.5 Ferring Pharmaceuticals
• 9.6 Fidia Pharma
• 9.7 GlaxoSmithKline (GSK)
• 9.8 Haleon
• 9.9 Kenvue
• 9.10 Organon LLC
• 9.11 Pacira Pharmaceuticals
• 9.12 Pfizer
• 9.13 Premier Surgical
• 9.14 Sanofi
• 9.15 Stellar Pharmaceuticals